Figure 2:
(A) Time-related prevalence of class I/III anti-arrhythmic use after a hybrid monolateral approach with a monopolar device. (B) Time-related prevalence of class I/III anti-arrhythmic use after a hybrid bilateral approach with bipolar device. (C) Time-related prevalence of Warfarin use after a hybrid monolateral approach with a monopolar device. (D) Time-related prevalence of Warfarin use after a hybrid bilateral approach with bipolar device.